{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T01:53:22Z","timestamp":1792288402139,"version":"4.4.0"},"reference-count":124,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005930","name":"Brain and Behavior Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005930","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001455","name":"American Foundation for Suicide Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001455","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.jns.2020.116778","type":"journal-article","created":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T17:29:58Z","timestamp":1584638998000},"page":"116778","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"special_numbering":"C","title":["Ketamine and nitrous oxide: The evolution of NMDA receptor antagonists as antidepressant agents"],"prefix":"10.1016","volume":"412","author":[{"given":"Molly C.","family":"Kalmoe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin M.","family":"Janski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles F.","family":"Zorumski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Nagele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben J.","family":"Palanca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6849-9416","authenticated-orcid":false,"given":"Charles R.","family":"Conway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jns.2020.116778_bb0005","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.jns.2020.116778_bb0010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/jamapsychiatry.2016.2586","article-title":"Toward an evidence-based, operational definition of treatment-resistant depression: when enough is enough","volume":"74","author":"Conway","year":"2017","journal-title":"JAMA Psychiatry."},{"key":"10.1016\/j.jns.2020.116778_bb0015","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.pnpbp.2015.02.015","article-title":"Role of calcium, glutamate and NMDA in major depression and therapeutic application","volume":"64","author":"Deutschenbaur","year":"2016","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.jns.2020.116778_bb0020","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/HRP.0000000000000183","article-title":"Glutamatergic modulators in depression","volume":"26","author":"Henter","year":"2018","journal-title":"Harv Rev Psychiatry"},{"issue":"4","key":"10.1016\/j.jns.2020.116778_bb0025","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s40265-017-0702-8","article-title":"Ketamine and beyond: investigations into the potential of glutamatergic agents to treat depression","volume":"77","author":"Lener","year":"2017","journal-title":"Drugs."},{"issue":"7","key":"10.1016\/j.jns.2020.116778_bb0030","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nrd.2017.16","article-title":"Targeting glutamate signalling in depression: progress and prospects","volume":"16","author":"Murrough","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jns.2020.116778_bb0035","author":"Medicine NUSNLo"},{"key":"10.1016\/j.jns.2020.116778_bb0040","series-title":"Ketalar FDA label","year":"2018"},{"issue":"1","key":"10.1016\/j.jns.2020.116778_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-2999(90)90204-J","article-title":"Functional antagonists at the NMDA receptor complex exhibit antidepressant actions","volume":"185","author":"Trullas","year":"1990","journal-title":"Eur. J. Pharmacol."},{"issue":"1\u20132","key":"10.1016\/j.jns.2020.116778_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-2999(94)90516-9","article-title":"Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression","volume":"263","author":"Papp","year":"1994","journal-title":"Eur. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.jns.2020.116778_bb0055","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S2215-0366(17)30077-9","article-title":"Ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT): a multicentre, double-blind, randomised, parallel-group, superiority trial","volume":"4","author":"Anderson","year":"2017","journal-title":"Lancet Psychiatry"},{"issue":"6","key":"10.1016\/j.jns.2020.116778_bb0060","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s12630-018-1088-0","article-title":"Ketamine-based anesthesia improves electroconvulsive therapy outcomes: a randomized-controlled study","volume":"65","author":"Gamble","year":"2018","journal-title":"Can. J. Anaesth."},{"issue":"1\u20133","key":"10.1016\/j.jns.2020.116778_bb0065","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jad.2012.04.032","article-title":"Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial","volume":"142","author":"Loo","year":"2012","journal-title":"J. Affect. Disord."},{"issue":"3","key":"10.1016\/j.jns.2020.116778_bb0070","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/YCT.0b013e3181c3b0aa","article-title":"Rapid antidepressant effect of ketamine anesthesia during electroconvulsive therapy of treatment-resistant depression: comparing ketamine and propofol anesthesia","volume":"26","author":"Okamoto","year":"2010","journal-title":"J ECT."},{"issue":"4","key":"10.1016\/j.jns.2020.116778_bb0075","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/ANA.0000000000000511","article-title":"Ketamine anesthesia does not improve depression scores in electroconvulsive therapy: a randomized clinical trial","volume":"30","author":"Carspecken","year":"2018","journal-title":"J. Neurosurg. Anesthesiol."},{"issue":"3","key":"10.1016\/j.jns.2020.116778_bb0080","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/YCT.0b013e318283b7e9","article-title":"Effects of S-ketamine as an anesthetic adjuvant to propofol on treatment response to electroconvulsive therapy in treatment-resistant depression: a randomized pilot study","volume":"29","author":"Jarventausta","year":"2013","journal-title":"J ECT."},{"key":"10.1016\/j.jns.2020.116778_bb0085","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jad.2017.11.034","article-title":"A randomized clinical trial of adjunctive ketamine anesthesia in electro-convulsive therapy for depression","volume":"227","author":"Zhang","year":"2018","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jns.2020.116778_bb0090","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jad.2016.05.011","article-title":"Mood and neuropsychological effects of different doses of ketamine in electroconvulsive therapy for treatment-resistant depression","volume":"201","author":"Zhong","year":"2016","journal-title":"J. Affect. Disord."},{"issue":"3","key":"10.1016\/j.jns.2020.116778_bb0095","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","article-title":"Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses","volume":"51","author":"Krystal","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"issue":"4","key":"10.1016\/j.jns.2020.116778_bb0100","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol. Psychiatry"},{"issue":"8","key":"10.1016\/j.jns.2020.116778_bb0105","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"issue":"12","key":"10.1016\/j.jns.2020.116778_bb0110","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4088\/JCP.09m05327blu","article-title":"Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder","volume":"71","author":"DiazGranados","year":"2010","journal-title":"J Clin Psychiatry."},{"issue":"10","key":"10.1016\/j.jns.2020.116778_bb0115","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","article-title":"Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial","volume":"170","author":"Murrough","year":"2013","journal-title":"Am. J. Psychiatry"},{"issue":"8","key":"10.1016\/j.jns.2020.116778_bb0120","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/archgenpsychiatry.2010.90","article-title":"A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression","volume":"67","author":"Diazgranados","year":"2010","journal-title":"Arch. Gen. Psychiatry"},{"issue":"11","key":"10.1016\/j.jns.2020.116778_bb0125","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.biopsych.2011.12.010","article-title":"Replication of ketamine\u2019s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial","volume":"71","author":"Zarate","year":"2012","journal-title":"Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.jns.2020.116778_bb0130","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.pnpbp.2011.03.019","article-title":"Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression","volume":"35","author":"Ibrahim","year":"2011","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.jns.2020.116778_bb0135","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1176\/appi.ajp.2017.17060647","article-title":"Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial","volume":"175","author":"Grunebaum","year":"2018","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.jns.2020.116778_bb0140","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.biopsych.2009.08.038","article-title":"Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression","volume":"67","author":"aan het Rot","year":"2010","journal-title":"Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.jns.2020.116778_bb0145","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.biopsych.2012.06.022","article-title":"Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression","volume":"74","author":"Murrough","year":"2013","journal-title":"Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.jns.2020.116778_bb0150","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1177\/0269881113478283","article-title":"Serial infusions of low-dose ketamine for major depression","volume":"27","author":"Rasmussen","year":"2013","journal-title":"J. Psychopharmacol."},{"issue":"9","key":"10.1016\/j.jns.2020.116778_bb0155","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/jcph.122","article-title":"Repeated S-ketamine infusions in therapy resistant depression: a case series","volume":"53","author":"Segmiller","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jns.2020.116778_bb0160","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jad.2013.10.036","article-title":"Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression","volume":"155","author":"Shiroma","year":"2014","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jns.2020.116778_bb0165","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jpsychires.2014.07.027","article-title":"Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety","volume":"58","author":"Ballard","year":"2014","journal-title":"J. Psychiatr. Res."},{"issue":"8","key":"10.1016\/j.jns.2020.116778_bb0170","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1176\/appi.ajp.2016.16010037","article-title":"A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression","volume":"173","author":"Singh","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jns.2020.116778_bb0175","article-title":"Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)","author":"Fava","year":"2018","journal-title":"Mol. Psychiatry"},{"issue":"2","key":"10.1016\/j.jns.2020.116778_bb0180","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/00000542-200202000-00022","article-title":"Cognitive impairment after small-dose ketamine isomers in comparison to equianalgesic racemic ketamine in human volunteers","volume":"96","author":"Pfenninger","year":"2002","journal-title":"Anesthesiology."},{"issue":"12","key":"10.1016\/j.jns.2020.116778_bb0185","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.biopsych.2014.03.026","article-title":"A randomized controlled trial of intranasal ketamine in major depressive disorder","volume":"76","author":"Lapidus","year":"2014","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.jns.2020.116778_bb0190","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","article-title":"Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial","volume":"75","author":"Daly","year":"2018","journal-title":"JAMA Psychiatry"},{"issue":"7","key":"10.1016\/j.jns.2020.116778_bb0195","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1176\/appi.ajp.2018.17060720","article-title":"Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study","volume":"175","author":"Canuso","year":"2018","journal-title":"Am. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.jns.2020.116778_bb0200","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study","volume":"176","author":"Popova","year":"2019","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.jns.2020.116778_bb0205","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/jamapsychiatry.2017.0080","article-title":"A consensus statement on the use of ketamine in the treatment of mood disorders","volume":"74","author":"Sanacora","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"7","key":"10.1016\/j.jns.2020.116778_bb0210","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1089\/jpm.2010.9808","article-title":"Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care","volume":"13","author":"Irwin","year":"2010","journal-title":"J. Palliat. Med."},{"issue":"2","key":"10.1016\/j.jns.2020.116778_bb0215","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/npp.2017.194","article-title":"Ketamine for social anxiety disorder: a randomized, placebo-controlled crossover trial","volume":"43","author":"Taylor","year":"2018","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.jns.2020.116778_bb0220","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212305","article-title":"Ketamine as treatment for post-traumatic stress disorder: a review","volume":"8","author":"Liriano","year":"2019","journal-title":"Drugs Context"},{"issue":"1","key":"10.1016\/j.jns.2020.116778_bb0225","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/0269881116667709","article-title":"Subanesthetic ketamine decreases the incentive-motivational value of reward-related cues","volume":"31","author":"Fitzpatrick","year":"2017","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.jns.2020.116778_bb0230","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1186\/s12888-016-1112-2","article-title":"Experience of the use of ketamine to manage opioid withdrawal in an addicted woman: a case report","volume":"16","author":"Lalanne","year":"2016","journal-title":"BMC Psychiatry."},{"issue":"1","key":"10.1016\/j.jns.2020.116778_bb0235","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2215-0366(17)30272-9","article-title":"Side-effects associated with ketamine use in depression: a systematic review","volume":"5","author":"Short","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"Pt 1","key":"10.1016\/j.jns.2020.116778_bb0240","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.brainresbull.2016.05.016","article-title":"Ketamine abuse potential and use disorder","volume":"126","author":"Liu","year":"2016","journal-title":"Brain Res. Bull."},{"issue":"3","key":"10.1016\/j.jns.2020.116778_bb0245","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.drugalcdep.2008.01.024","article-title":"Journey through the K-hole: phenomenological aspects of ketamine use","volume":"95","author":"Muetzelfeldt","year":"2008","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"10.1016\/j.jns.2020.116778_bb0250","first-page":"31","article-title":"Ketamine associated psychedelic effects and dependence","volume":"44","author":"Lim","year":"2003","journal-title":"Singap. Med. J."},{"issue":"6","key":"10.1016\/j.jns.2020.116778_bb0255","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1177\/0897190014525754","article-title":"Ketamine: an update on its abuse","volume":"27","author":"Bokor","year":"2014","journal-title":"J. Pharm. Pract."},{"issue":"3","key":"10.1016\/j.jns.2020.116778_bb0260","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1176\/appi.ajp.2015.15081082","article-title":"Potential risks of poorly monitored ketamine use in depression treatment","volume":"173","author":"Schak","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jns.2020.116778_bb0265","series-title":"Spravato REMS Fact Sheet","year":"2019"},{"key":"10.1016\/j.jns.2020.116778_bb0270","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.pharmthera.2019.02.017","article-title":"Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies","volume":"199","author":"Pham","year":"2019","journal-title":"Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.jns.2020.116778_bb0275","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.neuron.2019.02.005","article-title":"Ketamine: a paradigm shift for depression research and treatment","volume":"101","author":"Krystal","year":"2019","journal-title":"Neuron."},{"issue":"3","key":"10.1016\/j.jns.2020.116778_bb0280","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.117.015198","article-title":"Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms","volume":"70","author":"Zanos","year":"2018","journal-title":"Pharmacol. Rev."},{"issue":"4","key":"10.1016\/j.jns.2020.116778_bb0285","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/mp.2017.255","article-title":"Mechanisms of ketamine action as an antidepressant","volume":"23","author":"Zanos","year":"2018","journal-title":"Mol. Psychiatry"},{"issue":"3","key":"10.1016\/j.jns.2020.116778_bb0290","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40263-018-0492-x","article-title":"Convergent mechanisms underlying rapid antidepressant action","volume":"32","author":"Zanos","year":"2018","journal-title":"CNS Drugs."},{"key":"10.1016\/j.jns.2020.116778_bb0295","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3389\/fpsyt.2015.00172","article-title":"Treatment-resistant major depression: rationale for NMDA receptors as targets and nitrous oxide as therapy","volume":"6","author":"Zorumski","year":"2015","journal-title":"Front. Psychiatry"},{"issue":"5","key":"10.1016\/j.jns.2020.116778_bb0300","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1007\/s12035-018-1306-3","article-title":"Crosstalk between inflammation and glutamate system in depression: signaling pathway and molecular biomarkers for Ketamine\u2019s antidepressant effect","volume":"56","author":"Cui","year":"2019","journal-title":"Mol. Neurobiol."},{"issue":"6436","key":"10.1016\/j.jns.2020.116778_bb0305","doi-asserted-by":"crossref","DOI":"10.1126\/science.aat8078","article-title":"Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation","volume":"364","author":"Moda-Sava","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.jns.2020.116778_bb0310","doi-asserted-by":"crossref","DOI":"10.1177\/2470547019852073","article-title":"Does the opioid system block or enhance the antidepressant effects of ketamine?","volume":"3","author":"Mathew","year":"2019","journal-title":"Chronic Stress"},{"issue":"4","key":"10.1016\/j.jns.2020.116778_bb0315","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.euroneuro.2019.02.008","article-title":"Functional connectivity between prefrontal cortex and subgenual cingulate predicts antidepressant effects of ketamine","volume":"29","author":"Gartner","year":"2019","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"6","key":"10.1016\/j.jns.2020.116778_bb0320","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/npp.2016.186","article-title":"Ketamine treatment and global brain connectivity in major depression","volume":"42","author":"Abdallah","year":"2017","journal-title":"Neuropsychopharmacology."},{"issue":"6","key":"10.1016\/j.jns.2020.116778_bb0325","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/HRP.0000000000000179","article-title":"Ketamine-associated brain changes: a review of the neuroimaging literature","volume":"26","author":"Ionescu","year":"2018","journal-title":"Harv. Rev. Psychiatry"},{"issue":"7","key":"10.1016\/j.jns.2020.116778_bb0330","first-page":"610","article-title":"Effects of ketamine on brain activity during emotional processing: differential findings in depressed versus healthy control participants","volume":"4","author":"Reed","year":"2019","journal-title":"Biol. Psychiatry Cogn. Neurosci. Neuroimaging."},{"issue":"8","key":"10.1016\/j.jns.2020.116778_bb0335","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.biopsych.2018.01.027","article-title":"Default mode connectivity in major depressive disorder measured up to 10 days after ketamine administration","volume":"84","author":"Evans","year":"2018","journal-title":"Biol. Psychiatry"},{"issue":"7","key":"10.1016\/j.jns.2020.116778_bb0340","first-page":"603","article-title":"Harnessing neuroimaging to enhance our understanding of the effects of ketamine in depression","volume":"4","author":"Jaworska","year":"2019","journal-title":"Biol. Psychiatry Cogn. Neurosci. Neuroimaging"},{"issue":"7604","key":"10.1016\/j.jns.2020.116778_bb0345","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos","year":"2016","journal-title":"Nature."},{"issue":"8","key":"10.1016\/j.jns.2020.116778_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopsych.2016.06.029","article-title":"Antidepressant actions of ketamine versus hydroxynorketamine","volume":"81","author":"Collingridge","year":"2017","journal-title":"Biol. Psychiatry"},{"issue":"7659","key":"10.1016\/j.jns.2020.116778_bb0355","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1038\/nature22084","article-title":"Effects of a ketamine metabolite on synaptic NMDAR function","volume":"546","author":"Suzuki","year":"2017","journal-title":"Nature."},{"issue":"8","key":"10.1016\/j.jns.2020.116778_bb0360","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1016\/j.biopsych.2016.08.039","article-title":"Reply to: antidepressant actions of ketamine versus hydroxynorketamine","volume":"81","author":"Zanos","year":"2017","journal-title":"Biol. Psychiatry"},{"issue":"44","key":"10.1016\/j.jns.2020.116778_bb0365","doi-asserted-by":"crossref","first-page":"11158","DOI":"10.1523\/JNEUROSCI.1547-16.2016","article-title":"Ketamine: NMDA receptors and beyond","volume":"36","author":"Zorumski","year":"2016","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.jns.2020.116778_bb0370","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.biopsych.2012.03.004","article-title":"Relationship of ketamine\u2019s plasma metabolites with response, diagnosis, and side effects in major depression","volume":"72","author":"Zarate","year":"2012","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.jns.2020.116778_bb0375","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/npp.2017.210","article-title":"The ketamine metabolite 2R,6R-hydroxynorketamine blocks NMDA receptors and impacts downstream signaling linked to antidepressant effects","volume":"43","author":"Kavalali","year":"2018","journal-title":"Neuropsychopharmacology."},{"issue":"7659","key":"10.1016\/j.jns.2020.116778_bb0380","doi-asserted-by":"crossref","first-page":"E4","DOI":"10.1038\/nature22085","article-title":"Zanos et al. reply","volume":"546","author":"Zanos","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jns.2020.116778_bb0385","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.neuropharm.2019.04.019","article-title":"Pharmacological evaluation of clinically relevant concentrations of (2R,6R)-hydroxynorketamine","volume":"153","author":"Shaffer","year":"2019","journal-title":"Neuropharmacology."},{"issue":"9","key":"10.1016\/j.jns.2020.116778_bb0390","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","article-title":"Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial","volume":"76","author":"Daly","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"10","key":"10.1016\/j.jns.2020.116778_bb0395","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/ijnp\/pyz039","article-title":"Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1)","volume":"22","author":"Fedgchin","year":"2019","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"12","key":"10.1016\/j.jns.2020.116778_bb0400","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1176\/appi.ajp.2018.18020138","article-title":"Attenuation of antidepressant effects of ketamine by opioid receptor antagonism","volume":"175","author":"Williams","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jns.2020.116778_bb0405","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.brainres.2014.03.026","article-title":"Central antinociception induced by ketamine is mediated by endogenous opioids and mu- and delta-opioid receptors","volume":"1562","author":"Pacheco","year":"2014","journal-title":"Brain Res."},{"issue":"5","key":"10.1016\/j.jns.2020.116778_bb0410","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1073\/pnas.1916570117","article-title":"Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents","volume":"117","author":"Klein","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"12","key":"10.1016\/j.jns.2020.116778_bb0415","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1176\/appi.ajp.2018.18070800","article-title":"Is there really nothing new under the sun? Is low-dose ketamine a fast-acting antidepressant simply because it is an opioid?","volume":"175","author":"George","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jns.2020.116778_bb0420","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3389\/fpsyt.2018.00277","article-title":"Efficacy of ketamine in the treatment of substance use disorders: a systematic review","volume":"9","author":"Jones","year":"2018","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.jns.2020.116778_bb0425","first-page":"270","article-title":"A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: a randomized clinical trial","volume":"142","author":"Dakwar","year":"2019","journal-title":"Am. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.jns.2020.116778_bb0430","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1176\/appi.ajp.2019.19040423","article-title":"A word to the wise about intranasal esketamine","volume":"176","author":"Schatzberg","year":"2019","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.jns.2020.116778_bb0435","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/jamapsychiatry.2018.3990","article-title":"Association of combined naltrexone and ketamine with depressive symptoms in a case series of patients with depression and alcohol use disorder","volume":"76","author":"Yoon","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"10.1016\/j.jns.2020.116778_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopsych.2018.11.006","article-title":"Lack of opioid system in the antidepressant actions of ketamine","volume":"85","author":"Zhang","year":"2019","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.jns.2020.116778_bb0445","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1176\/appi.ajp.2018.18111231","article-title":"Attenuation of antidepressant effects of ketamine by opioid receptor antagonism: is it a ketamine-specific effect?","volume":"176","author":"Amiaz","year":"2019","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.jns.2020.116778_bb0450","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1176\/appi.ajp.2019.19010044","article-title":"Explaining naltrexone\u2019s interference with ketamine\u2019s antidepressant effect","volume":"176","author":"Wang","year":"2019","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.jns.2020.116778_bb0455","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/ALN.0b013e3181870a17","article-title":"Biologic effects of nitrous oxide: a mechanistic and toxicologic review","volume":"109","author":"Sanders","year":"2008","journal-title":"Anesthesiology."},{"issue":"2","key":"10.1016\/j.jns.2020.116778_bb0460","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/JCP.0000000000000837","article-title":"Exploring nitrous oxide as treatment of mood disorders: basic concepts","volume":"38","author":"Nagele","year":"2018","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.jns.2020.116778_bb0465","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1213\/ANE.0b013e3182a7f73c","article-title":"Nitrous oxide for the management of labor pain: a systematic review","volume":"118","author":"Likis","year":"2014","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.jns.2020.116778_bb0470","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40138-016-0092-3","article-title":"Nitrous oxide, from the operating room to the emergency department","volume":"4","author":"Huang","year":"2016","journal-title":"Curr. Emerg. Hosp. Med. Rep."},{"issue":"2","key":"10.1016\/j.jns.2020.116778_bb0475","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/PEC.0b013e318280d824","article-title":"Applications of nitrous oxide for procedural sedation in the pediatric population","volume":"29","author":"Tobias","year":"2013","journal-title":"Pediatr. Emerg. Care"},{"issue":"5","key":"10.1016\/j.jns.2020.116778_bb0480","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.mehy.2009.11.021","article-title":"Nitrous oxide (laughing gas) inhalation as an alternative to electroconvulsive therapy","volume":"74","author":"Milne","year":"2010","journal-title":"Med. Hypotheses"},{"issue":"1","key":"10.1016\/j.jns.2020.116778_bb0485","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.biopsych.2014.11.016","article-title":"Nitrous oxide for treatment-resistant major depression: a proof-of-concept trial","volume":"78","author":"Nagele","year":"2015","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.jns.2020.116778_bb0490","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.yrtph.2015.10.017","article-title":"Recreational nitrous oxide use: prevalence and risks","volume":"73","author":"van Amsterdam","year":"2015","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"5","key":"10.1016\/j.jns.2020.116778_bb0495","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.braindev.2018.12.003","article-title":"Recreational nitrous oxide abuse related subacute combined degeneration of the spinal cord in adolescents \u2013 a case series and literature review","volume":"41","author":"Lan","year":"2019","journal-title":"Brain Dev."},{"issue":"4","key":"10.1016\/j.jns.2020.116778_bb0500","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8040551","article-title":"Global burden related to nitrous oxide exposure in medical and recreational settings: a systematic review and individual patient data meta-analysis","volume":"8","author":"Oussalah","year":"2019","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.jns.2020.116778_bb0505","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0002-9343(86)90189-0","article-title":"Nitrous oxide, an opioid addictive agent. Review of the evidence","volume":"81","author":"Gillman","year":"1986","journal-title":"Am. J. Med."},{"key":"10.1016\/j.jns.2020.116778_bb0510","author":"Medicine NUSNLo"},{"issue":"4","key":"10.1016\/j.jns.2020.116778_bb0515","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/nm0498-460","article-title":"Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin","volume":"4","author":"Jevtovic-Todorovic","year":"1998","journal-title":"Nat. Med."},{"issue":"23","key":"10.1016\/j.jns.2020.116778_bb0520","doi-asserted-by":"crossref","first-page":"9716","DOI":"10.1523\/JNEUROSCI.18-23-09716.1998","article-title":"Effect of nitrous oxide on excitatory and inhibitory synaptic transmission in hippocampal cultures","volume":"18","author":"Mennerick","year":"1998","journal-title":"J. Neurosci."},{"issue":"23","key":"10.1016\/j.jns.2020.116778_bb0525","doi-asserted-by":"crossref","first-page":"8791","DOI":"10.1073\/pnas.0402825101","article-title":"Nitrous oxide (N(2)O) requires the N-methyl-D-aspartate receptor for its action in Caenorhabditis elegans","volume":"101","author":"Nagele","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.jns.2020.116778_bb0530","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/00000542-200503000-00013","article-title":"Effect of N-methyl-D-aspartate receptor epsilon1 subunit gene disruption of the action of general anesthetic drugs in mice","volume":"102","author":"Sato","year":"2005","journal-title":"Anesthesiology."},{"issue":"4","key":"10.1016\/j.jns.2020.116778_bb0535","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00000542-200010000-00034","article-title":"Effects of gaseous anesthetics nitrous oxide and xenon on ligand-gated ion channels: comparison with isoflurane and ethanol","volume":"93","author":"Yamakura","year":"2000","journal-title":"Anesthesiology."},{"issue":"3","key":"10.1016\/j.jns.2020.116778_bb0540","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0026-895X(24)12624-7","article-title":"Ca(v)3.2 channel is a molecular substrate for inhibition of T-type calcium currents in rat sensory neurons by nitrous oxide","volume":"60","author":"Todorovic","year":"2001","journal-title":"Mol. Pharmacol."},{"issue":"4","key":"10.1016\/j.jns.2020.116778_bb0545","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ceca.2009.09.002","article-title":"Structural and biophysical determinants of single Ca(V)3.1 and Ca(V)3.2 T-type calcium channel inhibition by N(2)O","volume":"46","author":"Bartels","year":"2009","journal-title":"Cell Calcium"},{"issue":"1","key":"10.1016\/j.jns.2020.116778_bb0550","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1113\/jphysiol.2010.196220","article-title":"Free radical signalling underlies inhibition of Ca(V)3.2 T-type calcium channels by nitrous oxide in the pain pathway","volume":"589","author":"Orestes","year":"2011","journal-title":"J. Physiol.-Lond."},{"issue":"2","key":"10.1016\/j.jns.2020.116778_bb0555","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1124\/mol.65.2.443","article-title":"Two-pore-domain K+ channels are a novel target for the anesthetic gases xenon, nitrous oxide, and cyclopropane","volume":"65","author":"Gruss","year":"2004","journal-title":"Mol. Pharmacol."},{"issue":"1\u20132","key":"10.1016\/j.jns.2020.116778_bb0560","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0014-2999(83)90626-X","article-title":"[3H]naloxone displacement: evidence for nitrous oxide as opioid receptor agonist","volume":"89","author":"Daras","year":"1983","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.jns.2020.116778_bb0565","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/00000542-198903000-00027","article-title":"Effects of nitrous-oxide and halothane on mu-opioid and kappa-opioid receptors in guinea-pig brain","volume":"70","author":"Ori","year":"1989","journal-title":"Anesthesiology."},{"issue":"2\u20133","key":"10.1016\/j.jns.2020.116778_bb0570","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0014-2999(97)01219-3","article-title":"Opiate receptors in the periaqueductal gray mediate analgesic effect of nitrous oxide in rats","volume":"336","author":"Fang","year":"1997","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.jns.2020.116778_bb0575","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1097\/00000542-200310000-00030","article-title":"Brain stem opioidergic and GABAergic neurons mediate the antinociceptive effect of nitrous oxide in Fischer rats","volume":"99","author":"Ohashi","year":"2003","journal-title":"Anesthesiology"},{"issue":"2","key":"10.1016\/j.jns.2020.116778_bb0580","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00540-010-0886-5","article-title":"Involvement of the kappa-opioid receptor in nitrous oxide-induced analgesia in mice","volume":"24","author":"Koyama","year":"2010","journal-title":"J. Anesth."},{"issue":"6","key":"10.1016\/j.jns.2020.116778_bb0585","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1093\/bja\/aeu254","article-title":"Kappa-opioid receptor mediates the antinociceptive effect of nitrous oxide in mice","volume":"113","author":"Fukagawa","year":"2014","journal-title":"Br. J. Anaesth."},{"issue":"24","key":"10.1016\/j.jns.2020.116778_bb0590","doi-asserted-by":"crossref","first-page":"9242","DOI":"10.1523\/JNEUROSCI.20-24-09242.2000","article-title":"Antinociceptive action of nitrous oxide is mediated by stimulation of noradrenergic neurons in the brainstem and activation of [alpha]2B adrenoceptors","volume":"20","author":"Sawamura","year":"2000","journal-title":"J. Neurosci."},{"issue":"6","key":"10.1016\/j.jns.2020.116778_bb0595","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1097\/00000542-200212000-00018","article-title":"Evidence for the involvement of spinal cord alpha1 adrenoceptors in nitrous oxide-induced antinociceptive effects in Fischer rats","volume":"97","author":"Orii","year":"2002","journal-title":"Anesthesiology"},{"issue":"1","key":"10.1016\/j.jns.2020.116778_bb0600","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/00000542-200501000-00034","article-title":"Nitrous oxide (laughing gas) facilitates excitability in rat hippocampal slices through gamma-aminobutyric acid A receptor-mediated disinhibition","volume":"102","author":"Nagashima","year":"2005","journal-title":"Anesthesiology"},{"key":"10.1016\/j.jns.2020.116778_bb0605","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3389\/fncel.2018.00135","article-title":"Nitrous oxide induces prominent cell proliferation in adult rat hippocampal dentate gyrus","volume":"12","author":"Chamaa","year":"2018","journal-title":"Front. Cell. Neurosci."},{"issue":"2","key":"10.1016\/j.jns.2020.116778_bb0610","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056434","article-title":"Modulation of functional EEG networks by the NMDA antagonist nitrous oxide","volume":"8","author":"Kuhlmann","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jns.2020.116778_bb0615","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.clinph.2012.08.007","article-title":"Effects of nitrous oxide sedation on resting electroencephalogram topography","volume":"124","author":"Foster","year":"2013","journal-title":"Clin. Neurophysiol."},{"issue":"1","key":"10.1016\/j.jns.2020.116778_bb0620","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.clinph.2015.06.001","article-title":"Nitrous oxide-induced slow and delta oscillations","volume":"127","author":"Pavone","year":"2016","journal-title":"Clin. Neurophysiol."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X20301143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X20301143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:50:55Z","timestamp":1758383455000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X20301143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":124,"alternative-id":["S0022510X20301143"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2020.116778","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ketamine and nitrous oxide: The evolution of NMDA receptor antagonists as antidepressant agents","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2020.116778","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116778"}}